

Valeant Pharmaceuticals International, Inc.
Form 8-K
November 18, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of the earliest event reported): November 15, 2013 (November 15, 2013)

Valeant Pharmaceuticals International, Inc.

(Exact name of registrant as specified in its charter)

British Columbia, Canada
(State or other jurisdiction

of incorporation)

001-14956
(Commission

File Number)

98-0448205
(IRS Employer

Identification No.

Edgar Filing: Valeant Pharmaceuticals International, Inc. - Form 8-K

2150 St. Elzéar Blvd. West,

Laval, Quebec

Canada H7L 4A8

(Address of principal executive offices) (Zip Code)

514-744-6792

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events.

Redemption of Notes

On November 15, 2013, Valeant Pharmaceuticals International, Inc. (the Company) issued a press release announcing that Valeant Pharmaceuticals International, a wholly owned subsidiary of the Company, will redeem \$450 million aggregate principal amount of its outstanding 6.50% Senior Notes due 2016 and has mailed an irrevocable notice of redemption for such notes. Valeant Pharmaceuticals International also intends to mail an irrevocable notice of redemption for the remaining \$465.5 million aggregate principal amount of such notes on or about December 2, 2013. The press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit

No.	Description of Exhibit
99.1	Press Release announcing redemption of notes, dated November 15, 2013

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VALEANT PHARMACEUTICALS
INTERNATIONAL, INC.

By: /s/ Howard B. Schiller

Name: Howard B. Schiller

Title: Executive Vice President and Chief
Financial Officer

Date: November 15, 2013

EXHIBIT INDEX

Exhibit

Number	Description
99.1	Press Release announcing redemption of notes, dated November 15, 2013